ESC Premium Access

Benefit of LDL-C lowering with evolocumab on cardiovascular outcomes by age & sex: an analysis of the FOURIER trial

Congress Presentation

About the speaker

Professor Peter S Sever

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
4 presentations
1 follower

4 more presentations in this session

PCSK9 Inhibitors - State of the art

Speaker: Professor J. Armitage (Oxford, GB)

Thumbnail

PCSK9-Inhibitor treatment of cardiovascular high risk patients in a real-world setting

Speaker: Doctor U. Kassner (Berlin, DE)

Thumbnail

Inhibition of PCSK9 reduces infarct size and arrhythmia susceptibility in cardiac ischeamia/reperfusion injury through attenuating mitochondrial dysfunction and increasing connexin43 phosphorylation

Speaker: Doctor S. Palee (Chiang Mai, TH)

Thumbnail

Future hurdles in PCSK9 - Inhibition.

Speaker: Professor E. Stein (Cincinnati, US)

Thumbnail

Access the full session

PCSK9 inhibitors - For the many or the few?

Speakers: Professor P. Sever, Professor J. Armitage, Doctor U. Kassner, Doctor S. Palee, Professor E. Stein
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk